- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
What have we learned from cancer immunotherapy in the last 3 years? ; volume:12 ; number:1 ; day:21 ; month:5 ; year:2014 ; pages:1-11 ; date:12.2014
Journal of translational medicine ; 12, Heft 1 (21.5.2014), 1-11, 12.2014
- Creator
-
Ascierto, Paolo A.
- Contributor
-
Marincola, Francesco M.
SpringerLink (Online service)
- DOI
-
10.1186/1479-5876-12-141
- URN
-
urn:nbn:de:1111-2016041449541
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ascierto, Paolo A.
- Marincola, Francesco M.
- SpringerLink (Online service)
Other Objects (12)
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Combination therapy: the next opportunity and challenge of medicine
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016
Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?
Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Combination therapy: the next opportunity and challenge of medicine
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016
Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?
Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Combination therapy: the next opportunity and challenge of medicine
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016
Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?
Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma